Calculate how many units to draw for your retatrutide dose. Pre-filled with clinical trial titration values and common vial sizes.
The retatrutide titration schedule referenced from Phase 2 clinical trials starts low and increases every 4 weeks. This graduated approach allows the body to adjust at each level before moving to the next.
| Weeks | Weekly Dose | mcg | Units (10mg/2mL) |
|---|---|---|---|
| 1 - 4 | 0.5 mg | 500 mcg | 10 IU |
| 5 - 8 | 1 mg | 1,000 mcg | 20 IU |
| 9 - 12 | 2 mg | 2,000 mcg | 40 IU |
| 13 - 16 | 4 mg | 4,000 mcg | 80 IU |
| 17 - 20 | 8 mg | 8,000 mcg | 160 IU |
| 21+ | 12 mg | 12,000 mcg | 240 IU |
Retatrutide vials are available in several sizes. The number of doses per vial depends on your current titration level and how much bacteriostatic water you use for reconstitution.
Retatrutide has a half-life of approximately 5 days, which supports once-weekly subcutaneous administration. Many users choose a consistent day each week for dosing.
Retatrutide is a triple GIP/GLP-1/Glucagon receptor agonist currently in Phase 2/3 clinical trials. Its mechanism activates three receptor pathways involved in appetite signaling and energy metabolism.
Clinical trial protocols start at the lowest dose and increase every 4 weeks across six titration steps. This graduated approach is referenced in published Phase 2 dosing schedules.
Reconstituted retatrutide is typically stored refrigerated at 2-8 degrees Celsius. Using bacteriostatic water (with benzyl alcohol) supports multi-use stability for 4-6 weeks.
1 mL = 100 units (IU) on a standard U-100 insulin syringe
Always use bacteriostatic water (not sterile water) for multi-use vials
Higher titration doses (8mg+) may require multiple syringe draws per dose
Steady-state concentration is typically reached after 4-5 weekly doses at the same level